Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response	e: 0.5							

	e conditions of ee Instruction																
Name and Address of Reporting Person*     Dube Michael P				2. Issuer Name <b>and</b> Ticker or Trading Symbol Intellia Therapeutics, Inc. [NTLA]					5. (CI	Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner							
<u> </u>	TIOHACI I	•											Ott:	ctor er (give title		Other (s	
	ELLIA TH	ERAPEUTICS,	(Middle) S, INC.		3. Date of Earliest Transaction (Month/Day/Year) 10/02/2024							VP, Chief Accounting Officer					
40 ERIE STREET; SUITE 130			4. If A	If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable						
(Street)	XIDGE M	A 0	2139									Lin	Forr	n filed by On		•	
(City)	(St	rate) (2	Zip)										Pers	son			
		Table	I - No	on-Deriva	tive S	Secui	rities Acc	quired	l, Dis	sposed of	, or Be	eneficia	ally Owi	ned			
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day)			Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3,						6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)				
							Code	v	Amount	(A) or (D)	Price	Trans	Transaction(s) (Instr. 3 and 4)			(111311. 4)	
Common Stock 10/0		10/02/20	024			S <sup>(1)</sup>		2,012	D	\$19.01	(2)	17,012		D			
		Tal	ble II							osed of, convertib				d			
1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)				action (Instr.	5. Number of Derivative Securities	Expiration D (Month/Day/		ate	Amount of De		8. Price of Derivative Security	9. Number derivative Securities Beneficiali		10. Ownership Form: Direct (D)	11. Nature of Indirect Beneficial Ownership

## **Explanation of Responses:**

1. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on October 1, 2024, and does not represent a volitional trade by the Reporting Person.

Exercisable

(D)

(A)

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.95 to \$19.01, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 2, 2024 at each separate price.

/s/ James Basta, attorney-infact 10/04/2024

\*\* Signature of Reporting Person Date

Amount or Number

Shares

Title

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.